JP2013506425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506425A5 JP2013506425A5 JP2012532307A JP2012532307A JP2013506425A5 JP 2013506425 A5 JP2013506425 A5 JP 2013506425A5 JP 2012532307 A JP2012532307 A JP 2012532307A JP 2012532307 A JP2012532307 A JP 2012532307A JP 2013506425 A5 JP2013506425 A5 JP 2013506425A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24801409P | 2009-10-02 | 2009-10-02 | |
| US61/248,014 | 2009-10-02 | ||
| PCT/US2010/050873 WO2011041518A1 (en) | 2009-10-02 | 2010-09-30 | Monoclonal antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506425A JP2013506425A (ja) | 2013-02-28 |
| JP2013506425A5 true JP2013506425A5 (https=) | 2014-05-15 |
| JP5883389B2 JP5883389B2 (ja) | 2016-03-15 |
Family
ID=43826649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532307A Active JP5883389B2 (ja) | 2009-10-02 | 2010-09-30 | モノクローナル抗体 |
Country Status (38)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
| WO2013185055A1 (en) | 2012-06-07 | 2013-12-12 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of pin1 |
| EP2968548B1 (en) * | 2013-03-15 | 2020-09-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| EP3091996B1 (en) * | 2014-01-11 | 2024-04-10 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Compositions and methods for in vitro assays of fibrin activity |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| SG11201910113PA (en) * | 2017-05-02 | 2019-11-28 | Nat Cancer Center Japan | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate |
| CA3178880A1 (en) | 2020-03-31 | 2021-10-07 | National Cancer Center | Fibrin-binding antibody and pharmaceutical composition containing antibody |
| WO2022133028A1 (en) * | 2020-12-16 | 2022-06-23 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Use of fibrin-targeting immunotherapy to reduce coronavirus pathogenesis |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
| US20240279321A1 (en) * | 2021-06-18 | 2024-08-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE |
| WO2022266539A2 (en) * | 2021-06-18 | 2022-12-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
| WO2024044583A1 (en) * | 2022-08-22 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Human anti-fibrin antibodies and uses thereof |
| EP4676499A2 (en) * | 2023-03-10 | 2026-01-14 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods and compositions for cellular immunotherapy- fib4 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| EP2314620B1 (en) * | 2004-05-27 | 2013-06-05 | Crucell Holland B.V. | Method of identifying binding molecules capable of neutralizing rabies virus |
| WO2007038407A2 (en) * | 2005-09-23 | 2007-04-05 | The Regents Of The University Of California | Compositions and methods for treating nervous system disorders |
-
2010
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 CA CA2774256A patent/CA2774256C/en active Active
- 2010-09-30 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 SM SM20170083T patent/SMT201700083T1/it unknown
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko not_active Expired - Fee Related
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/en active Active
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/en not_active Ceased
- 2010-09-30 PH PH1/2012/500551A patent/PH12012500551A1/en unknown
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
-
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
-
2017
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506425A5 (https=) | ||
| Picchianti Diamanti et al. | Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity | |
| Steeland et al. | A new venue of TNF targeting | |
| Tyagi et al. | Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization | |
| Rommer et al. | Monoclonal antibodies in treatment of multiple sclerosis | |
| HRP20170110T1 (hr) | Monoklonska protutijela | |
| US20210260113A1 (en) | Devices, methods, compositions and systems for the treatment of aging and age-related disorders | |
| JP2020511672A5 (https=) | ||
| JP2017079785A5 (https=) | ||
| JP2020510698A5 (https=) | ||
| JP6587609B2 (ja) | 強皮症治療のための抗ｃｃｌ２及び抗ｌｏｘｌ２併用療法 | |
| JP2015508757A5 (https=) | ||
| UA125382C2 (uk) | Антитіла проти людського vista та їх застосування | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| Zaza et al. | Monoclonal antibody therapy and renal transplantation: focus on adverse effects | |
| JP2013027404A5 (https=) | ||
| JP2019519475A (ja) | ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用 | |
| JP2023505492A5 (https=) | ||
| RU2008152769A (ru) | Гуманизированное антитело против остеопонтина человека | |
| WO2014149733A1 (en) | Pan-ELR+ CXC CHEMOKINE ANTIBODIES | |
| RU2014106933A (ru) | Способы и композиции для лечения аутоиммунных и воспалительных заболеваний | |
| Branda et al. | Human T-lymphotropic virus (HTLV): Epidemiology, genetic, pathogenesis, and future challenges | |
| PETERSON et al. | Molecular mimicry | |
| Matsuda et al. | Deciphering autoantibody landscape of systemic sclerosis through systems-based approach: insights from a B-cell depletion clinical trial | |
| US20180179275A1 (en) | Anti-ccl2 antibodies for treatment of scleroderma |